生物谷报道：Paladin Labs已经并购Dimethaid Health Care，后者拥有Pennsaid在加拿大的销售许可。Pennsaid是一种获得Health Canada批准用于治疗膝关节炎的药膏。Paladin Labs的总裁兼CEO Jonathan Ross Goodman称“Pennsaid为骨关节炎病人提供了一种非常好的治疗方法。该产品2005年上半年的销售额比去年同期增长了40％，公司预计 Pennsaid的品牌价值在2005年底将达到800至900万美元。这一并购使Paladin Labs在治疗关节炎的治疗药物上获得新的突破。
TORONTO and MONTREAL, Aug. 16 /CNW/ - Paladin Labs Inc. (TSX: PLB), a Canadian speciality pharmaceutical company, has acquired Dimethaid Health Care Ltd. (DHCL), a subsidiary of Dimethaid Research Inc. (TSX:DMX). DHCL owns the Canadian license for Pennsaid(R), a lotion approved by Health Canada for the treatment of symptoms of knee osteoarthritis.
In return for its ownership of DHCL, Dimethaid Research has received an up-front payment, a share in operating profits above minimum targets and a long-term supply agreement. "Pennsaid offers a valuable treatment option to
those suffering from osteoarthritis," said Jonathan Ross Goodman, president and CEO of Paladin Labs. "This is evidenced by the fact that for the first 6 months of 2005, Pennsaid sales increased by 40% versus last year. We expect
that Pennsaid will be an $8-9 million brand in Canada by the end of 2005." "This is an important transaction for Dimethaid as it provides funding to implement our business plan without an immediate public market financing that
would be dilutive to our shareholders. While we are giving up a portion of our Pennsaid Canadian revenue, we will continue to participate in Pennsaid's future Canadian success," said Dan Chicoine, chairman of Dimethaid. "We will
now continue discussions with a number of pharmaceutical companies interested in licensing Pennsaid and Pennsaid Plus for the United States."
About Paladin Labs Inc.
Paladin Labs, headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this
strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Paladin Web Site at www.paladinlabs.com.
About Dimethaid Research Inc.
Dimethaid Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Québec and Wanzleben, Germany. The Company develops targeted therapeutic drugs designed to produce minimal side effects. Dimethaid's two technology platforms focus on transcellular drug delivery and immune system regulation. Products are aimed at expanding treatment options in rheumatology, dermatology, oncology, immunology, and the therapeutic management of chronic
viral infections. For more information, please visit www.dimethaid.com.
This news release may contain forward-looking statements or predictions. These statements represent our judgement as of this date and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. Potential risks and uncertainties include, without limitation, those associated with product development, clinical trials, future revenues and profitability, and obtaining marketing approval and other factors. For additional information on risks and uncertainties related to the forward-looking statements, investors should consult the company's ongoing quarterly filings, annual reports and Annual Information Form and other filings found on SEDAR at www.sedar.com.
For further information: Dimethaid Research Inc., Peter Block,
(416) 848-1373, info@dimethaid.com; Paladin Labs Inc., Samira Sakhia,
Chief Financial Officer, (514) 340-5067, info@paladin-labs.com;
Archived images on this organization are searchable through CNW Photo Archive
website at http://photos.newswire.ca. Images are free to accredited members of
the media.
To request a free copy of this organization's annual report, please go to
http://www.newswire.ca and click on reports@cnw.
